| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5948193 | Atherosclerosis | 2012 | 8 Pages |
Abstract
⺠Abciximab has been shown to improve survival in STEMI patients undergoing primary angioplasty. ⺠Intracoronary administration, by providing of larger amount of drug at the occlusion, seems to be more effective as compared to intravenous administration. ⺠Contrasting data have been reported in small randomized trials. ⺠This is meta-analysis of 8 randomized trials shows that intracoronary abciximab is safe. Despite benefits in myocardial perfusion, it does not improve survival.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Giuseppe De Luca, Monica Verdoia, Harry Suryapranata,